Tolazamide
Clinical data | |
---|---|
Trade names | Tolinase |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682482 |
License data |
|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | metabolized in the liver to active metabolites |
Elimination half-life | 7 hours |
Excretion | Renal (85%) and fecal (7%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.013.262 |
Chemical and physical data | |
Formula | C14H21N3O3S |
Molar mass | 311.40 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Tolazamide is an oral blood glucose lowering drug used for people with Type 2 diabetes. It is part of the sulfonylurea family (ATC A10BB).
Synthesis
[edit]para-Toluenesulfonamide is converted to its carbamate with ethyl chloroformate in the presence of a base. Heating that intermediate with 1-amino-azepane leads to the displacement of the ethoxy group and the formation of tolazemide:[1]
Azepane proper would lead to [13078-23-4].
References
[edit]External links
[edit]- "Tolazamide". Medline Plus. U.S. National Library of Medicine.